GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » EV-to-EBITDA

Avalon Globocare (Avalon Globocare) EV-to-EBITDA : -2.18 (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avalon Globocare's enterprise value is $32.00 Mil. Avalon Globocare's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.69 Mil. Therefore, Avalon Globocare's EV-to-EBITDA for today is -2.18.

The historical rank and industry rank for Avalon Globocare's EV-to-EBITDA or its related term are showing as below:

ALBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -316.56   Med: -8.07   Max: 1719.2
Current: -2.18

During the past 10 years, the highest EV-to-EBITDA of Avalon Globocare was 1719.20. The lowest was -316.56. And the median was -8.07.

ALBT's EV-to-EBITDA is ranked worse than
100% of 1373 companies
in the Real Estate industry
Industry Median: 12.58 vs ALBT: -2.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Avalon Globocare's stock price is $0.34. Avalon Globocare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.570. Therefore, Avalon Globocare's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Avalon Globocare EV-to-EBITDA Historical Data

The historical data trend for Avalon Globocare's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare EV-to-EBITDA Chart

Avalon Globocare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.55 -7.84 -8.88 -8.04 -2.23

Avalon Globocare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.04 -5.26 -4.84 -4.64 -2.23

Competitive Comparison of Avalon Globocare's EV-to-EBITDA

For the Real Estate Services subindustry, Avalon Globocare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalon Globocare's EV-to-EBITDA Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Avalon Globocare's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avalon Globocare's EV-to-EBITDA falls into.



Avalon Globocare EV-to-EBITDA Calculation

Avalon Globocare's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=31.996/-14.686
=-2.18

Avalon Globocare's current Enterprise Value is $32.00 Mil.
Avalon Globocare's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avalon Globocare  (NAS:ALBT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Avalon Globocare's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.34/-1.570
=At Loss

Avalon Globocare's share price for today is $0.34.
Avalon Globocare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Avalon Globocare EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalon Globocare (Avalon Globocare) Business Description

Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Executives
Lourdes Felix director 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin director 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu director, 10 percent owner C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders director 431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu director 14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy director 611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola officer: Chief Financial Officer 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin director, officer: CEO and President C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li director C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li director, officer: Chief Operating Officer C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel director 33 ALPINE DRIVE, MORGANVILLE NJ 07751